Regeneron hits 52-week high after "standout" Q3

What happened

Regeneron Pharmaceuticals reached a new 52-week high on Friday after third-quarter net sales rose 36% year-over-year to $5.1 billion, driven mainly by strong sales of its asthma therapy Dupixent, which is marketed with Sanofi.

Confirmed

Global impact / market context

Strong Dupixent sales and broad product beats give Regeneron more cash to reinvest in its drug pipeline, which can support future revenue growth. Analysts cited see this momentum continuing, though one keeps a neutral Sector Perform rating rather than a buy.

Analyst inference

The article states Regeneron hit a 52-week high after strong quarterly results across key products. Analyst ratings and price targets differ, showing split views on further upside following the Sanofi partnership renegotiation, with one analyst citing an $810 target.

Analyst inference

What to watch

1. Watch whether Dupixent sales growth continues, since the article says it drove most of Regeneron's 36% year-over-year net sales increase to $5.1 billion in the third quarter. Confirmed
2. Track how the renegotiated Sanofi partnership affects reported Dupixent collaboration revenue, because one analyst said the first full quarter without development-balance repayments helped growth. Proposed
3. Monitor sales of Eylea and Libtayo plus pipeline progress, as analysts cited these products as key drivers and pointed to pipeline expansion as a source of future value creation. Analyst inference

Evidence

• seekingalpha.com